الفهرس | Only 14 pages are availabe for public view |
Abstract Background: Hepatocellular carcinoma (HCC) has been one of the main reasons of cancer-associated mortality. Despite the recent advances in the clinical management of liver cancer, the long-term prognosis of HCC is still dismal. Developing new treatment strategies for HCC could be one of the pressing needs. The biguanide Metformin is a first-line drug for treatment type II diabetes mellitus. In addition it is considered a promising prospect in lowering risk, treatment and prognosis of HCC, but its precise antitumor mechanisms remain unclear. Aim: This study aimed to assess the dose and duration effects of metformin on cancer cell viability and levels of gene expression of (glypican3, LncRNA -AF085935, VEGF, P53 and NFmB). Methods: The study was conducted in vitro on HCC cell line, HepG2. It was treated by different concentrations of metformin (5, 10 and 20oM) at different durations (24, 48 and 72 h) versus untreated control groups. Cells viability were evaluated by MTT assay, while gene expression of interesting genes was assessed by quantitative real time PCR. Finally we statically analyzed a correlation between glypican3 and lncRNA-AF085935, cell proliferation and each studied parameter i.e. Glypican3 and LncRNA-AF085935 expression among studied groups |